Drugs / GRF6021
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03981419 | Jul 2019 → Jan 2021 | — | Alkahest, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03713957 | Nov 2018 → Jul 2020 | Parkinson disease | Alkahest, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-03-08 | Grifols Therapeutics LLC | Results Alkahest to Present Positive Data from Completed Phase 2 Clinical Trial at the 15th International Conference on Alzheimer’s and Parkinson’s Disease grifols.com ↗
In its phase 2 clinical study of GRF6021 in subjects with PD and cognitive impairment, GRF6021 demonstrated positive effects on cognitive endpoints in PD patients with cognitive impairment and was safe and well tolerated by study participants. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-03-08 | Grifols Therapeutics LLC | Alkahest to Present Positive Data from Completed Phase 2 Clinical Trial at the 15th International Conference on Alzheimer’s and Parkinson’s Disease grifols.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GRF6021 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03981419 ↗ |
| Modality | Protein / enzyme biologic | “a plasma-derived product” NCT03713957 ↗ |
| Route | Intravenous | “administered as an intravenous (IV) infusion” NCT03713957 ↗ |